Literature DB >> 21219587

N-substituted glutamyl sulfonamides as inhibitors of glutamate carboxypeptidase II (GCP2).

Brian R Blank1, Pinar Alayoglu, William Engen, Joseph K Choi, Clifford E Berkman, Marc O Anderson.   

Abstract

Glutamate carboxypeptidase II (GCP2) is a membrane-bound cell-surface peptidase which is implicated in several neurological disorders and is also over-expressed in prostate tumor cells. There is a significant interest in the inhibition of GCP2 as a means of neuroprotection, while GCP2 inhibition as a method to treat prostate cancer remains a topic of further investigation. The key zinc-binding functional group of the well-characterized classes of GCP2 inhibitors (phosphonates and phosphoramidates) is tetrahedral and negatively charged at neutral pH, while glutamyl urea class of inhibitors possesses a planar and neutral zinc-binding group. This study introduces a new class of GCP2 inhibitors, N-substituted glutamyl sulfonamides, which possess a neutral tetrahedral zinc-binding motif. A library containing 15 secondary sulfonamides and 4 tertiary (N-methyl) sulfonamides was prepared and evaluated for inhibitory potency against purified GCP2 enzyme activity. While most inhibitors lacked potency at 100 μm, short alkyl sulfonamides exhibited promising low micromolar potency, with the optimal inhibitor in this series being glutamyl N-(propylsulfonamide) (2g). Lastly, molecular docking was used to develop a model to formulate an explanation for the relative inhibitory potencies employed for this class of inhibitors.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21219587      PMCID: PMC3055939          DOI: 10.1111/j.1747-0285.2011.01085.x

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  37 in total

Review 1.  Carbonic anhydrases: novel therapeutic applications for inhibitors and activators.

Authors:  Claudiu T Supuran
Journal:  Nat Rev Drug Discov       Date:  2008-02       Impact factor: 84.694

2.  High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen.

Authors:  Valerie Humblet; Rena Lapidus; Larry R Williams; Takashi Tsukamoto; Camilo Rojas; Pavel Majer; Bunda Hin; Shunsuke Ohnishi; Alec M De Grand; Atif Zaheer; Jürgen T Renze; Akira Nakayama; Barbara S Slusher; John V Frangioni
Journal:  Mol Imaging       Date:  2005 Oct-Dec       Impact factor: 4.488

Review 3.  Radionuclide imaging of tumor angiogenesis.

Authors:  Ingrid Dijkgraaf; Otto C Boerman
Journal:  Cancer Biother Radiopharm       Date:  2009-12       Impact factor: 3.099

4.  Blockade of NAALADase: a novel neuroprotective strategy based on limiting glutamate and elevating NAAG.

Authors:  J J Vornov; K Wozniak; M Lu; P Jackson; T Tsukamoto; E Wang; B Slusher
Journal:  Ann N Y Acad Sci       Date:  1999       Impact factor: 5.691

5.  Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization.

Authors:  Cyril Barinka; Youngjoo Byun; Crystal L Dusich; Sangeeta R Banerjee; Ying Chen; Mark Castanares; Alan P Kozikowski; Ronnie C Mease; Martin G Pomper; Jacek Lubkowski
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

Review 6.  Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents.

Authors:  Claudiu T Supuran; Angela Casini; Andrea Scozzafava
Journal:  Med Res Rev       Date:  2003-09       Impact factor: 12.944

7.  Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II.

Authors:  Cyril Barinka; Miroslava Rovenská; Petra Mlcochová; Klára Hlouchová; Anna Plechanovová; Pavel Majer; Takashi Tsukamoto; Barbara S Slusher; Jan Konvalinka; Jacek Lubkowski
Journal:  J Med Chem       Date:  2007-06-14       Impact factor: 7.446

8.  Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA).

Authors:  Sangeeta R Banerjee; Catherine A Foss; Mark Castanares; Ronnie C Mease; Youngjoo Byun; James J Fox; John Hilton; Shawn E Lupold; Alan P Kozikowski; Martin G Pomper
Journal:  J Med Chem       Date:  2008-07-19       Impact factor: 7.446

9.  Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.

Authors:  Jeroen R Mesters; Cyril Barinka; Weixing Li; Takashi Tsukamoto; Pavel Majer; Barbara S Slusher; Jan Konvalinka; Rolf Hilgenfeld
Journal:  EMBO J       Date:  2006-02-09       Impact factor: 11.598

Review 10.  Targeted therapies for prostate cancer against the prostate specific membrane antigen.

Authors:  U Elsässer-Beile; P Bühler; P Wolf
Journal:  Curr Drug Targets       Date:  2009-02       Impact factor: 3.465

View more
  4 in total

1.  RPF151, a novel capsaicin-like analogue: in vitro studies and in vivo preclinical antitumor evaluation in a breast cancer model.

Authors:  Adilson Kleber Ferreira; Maurício Temotheo Tavares; Kerly Fernanda Mesquita Pasqualoto; Ricardo Alexandre de Azevedo; Sarah Fernandes Teixeira; Wilson Alves Ferreira-Junior; Ariane Matiello Bertin; Paulo Luiz de-Sá-Junior; José Alexandre Marzagão Barbuto; Carlos Rogério Figueiredo; Yara Cury; Mariana Celestina Frojuello Costa Bernstorff Damião; Roberto Parise-Filho
Journal:  Tumour Biol       Date:  2015-04-20

2.  Radiofluorination of PSMA-HBED via Al(18)F(2+) Chelation and Biological Evaluations In Vitro.

Authors:  Noeen Malik; Benjamin Baur; Gordon Winter; Sven N Reske; Ambros J Beer; Christoph Solbach
Journal:  Mol Imaging Biol       Date:  2015-12       Impact factor: 3.488

3.  Secondary Sulfonamides as Effective Lactoperoxidase Inhibitors.

Authors:  Zeynep Köksal; Ramazan Kalin; Yasemin Camadan; Hande Usanmaz; Züleyha Almaz; İlhami Gülçin; Taner Gokcen; Ahmet Ceyhan Gören; Hasan Ozdemir
Journal:  Molecules       Date:  2017-05-24       Impact factor: 4.411

4.  Molecular network-based identification of competing endogenous RNAs and mRNA signatures that predict survival in prostate cancer.

Authors:  Ning Xu; Yu-Peng Wu; Hu-Bin Yin; Xue-Yi Xue; Xin Gou
Journal:  J Transl Med       Date:  2018-10-04       Impact factor: 5.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.